Ebola Virus Glycoprotein Domains Associated with Protective Efficacy
Ebola virus (EBOV) is the cause of sporadic outbreaks of human hemorrhagic disease in Africa, and the best-characterized virus in the filovirus family. The West African epidemic accelerated the clinical development of vaccines and therapeutics, leading to licensure of vaccines and antibody-based the...
Main Authors: | Bharti Bhatia, Wakako Furuyama, Thomas Hoenen, Heinz Feldmann, Andrea Marzi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/6/630 |
Similar Items
-
Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection
by: Andrea R. Menicucci, et al.
Published: (2019-05-01) -
Development of an Enzyme-Linked Immunosorbent Assay to Determine the Expression Dynamics of Ebola Virus Soluble Glycoprotein during Infection
by: Wakako Furuyama, et al.
Published: (2020-10-01) -
Vesicular Stomatitis Virus: From Agricultural Pathogen to Vaccine Vector
by: Guodong Liu, et al.
Published: (2021-08-01) -
Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
by: Emmie de Wit, et al.
Published: (2015-04-01) -
Vesicular Stomatitis Virus–Based Vaccines against Lassa and Ebola Viruses
by: Andrea Marzi, et al.
Published: (2015-02-01)